Alternative Data for Dynavax Technologies
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 18,605 | Sign up | Sign up | Sign up |
| X Followers | 792 | Sign up | Sign up | Sign up |
| X Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $40,000 | Sign up | Sign up | Sign up |
| Business Outlook | 54 | Sign up | Sign up | Sign up |
| Linkedin Employees | 309 | Sign up | Sign up | Sign up |
About Dynavax Technologies
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.
| Price | $15.50 |
| Target Price | Sign up |
| Volume | 7,106,122 |
| Market Cap | $1.82B |
| Year Range | $9.36 - $15.72 |
| Dividend Yield | 0% |
| PE Ratio | 58.75 |
| Analyst Rating | 100% buy |
| Industry | Drug Manufacturers |
In the news
Infectious Disease Clinical Trials Research Report 2026: $21.25 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FApril 24 - GlobeNewswire |
|
Advanced Melanoma Markets and Companies 2026-2030: Cumulative Revenue to Grow by $1.87 BillionMarch 30 - GlobeNewswire |
|
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
|
Herpes Zoster Market Poised for Robust Growth During the Forecast Period (2026–2036) Driven by Rising Incidence and Vaccine Adoption | DelveInsightMarch 9 - GlobeNewswire |
|
Heplisav-B Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035FMarch 9 - GlobeNewswire |
|
Prefilled Syringe Fill Finish Manufacturing Market, 2035: Industry Trends and Global Forecasts by Therapeutic Area, Syringe Barrel Material, Number of Barrel Chambers, Drug MoleculeFebruary 25 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 95M | 14M | 80M | 27M | 32M | 0.210 |
| Q2 '25 | 95M | 14M | 81M | 19M | 25M | 0.140 |
| Q1 '25 | 68M | 14M | 54M | -96M | -94M | -0.009 |
| Q4 '24 | 72M | 13M | 59M | 7.1M | 12M | 0.050 |
| Q3 '24 | 81M | 13M | 68M | 18M | 24M | 0.120 |
Insider Transactions View All
| Novack David F filed to sell 63,344 shares at $15.6. January 20 '26 |
| Novack David F filed to sell 111,451 shares at $15.5. December 29 '25 |
| Myers Scott Dunseth filed to buy 35,004 shares at $10.8. August 25 '25 |
| KROIN DAVID filed to sell 15,726,349 shares at $10.6. August 22 '25 |
| KROIN DAVID filed to sell 16,696,492 shares at $11. August 22 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$228.92 1% | 50 |
 |
Eli Lilly and CompanyLLY |
$988.09 1.7% | 65 |
 |
PfizerPFE |
$25.33 0% | 35 |
 |
AstrazenecaAZN |
$183.92 1.3% | 56 |
 |
AbbVieABBV |
$209.41 0.5% | 51 |
Read more about Dynavax Technologies (DVAX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
FAQ - Dynavax Technologies
The Market Cap of Dynavax Technologies is $1.82B.
As of today, Dynavax Technologies' PE (Price to Earnings) ratio is 58.75.
Currently, the price of one share of Dynavax Technologies stock is $15.50.
The DVAX stock price chart above provides a comprehensive visual representation of Dynavax Technologies' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Dynavax Technologies shares. Our platform offers an up-to-date DVAX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Dynavax Technologies (DVAX) does not offer dividends to its shareholders. Investors interested in Dynavax Technologies should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Dynavax Technologies are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
